A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 (pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer

Administered By

Awarded By

Contributors

Start/End

  • September 20, 2018 - September 30, 2022